Compare IDEXX Laboratories, Inc. (IDXX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Otis Worldwide Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Otis Worldwide Corp trades at $65.98 (market cap $25.17B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.66% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Otis Worldwide Corp for 66 Days on average.
| IDXX | OTIS | |
|---|---|---|
Market Cap | $40.43B | $25.17B |
Volume | 692,164 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $766.68 | $93.62 |
52-Week Low | $504.70 | $64.05 |
Typical Hold Time | 46 Days | 66 Days |
Enterprise Value | $41.32B | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Otis Worldwide trades at $65.95, showing modest daily gains of 0.32% but remains near its 52-week low. The stock faces technical bearish signals with mixed fundamental performance - revenue growth remains stable at $14.43B (2025) but recent quarters show earnings misses. Analyst consensus is divided with 7 buy, 7 hold, and 1 sell ratings, while the company navigates margin pressures and China market challenges.
The outlook balances Otis's dominant market position and service-driven cash flows against margin pressures and weak equipment demand. With a $87 consensus price target suggesting 32% upside, the stock offers value but requires monitoring of service margin recovery and China exposure. Key risks include persistent cost inflation and execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
